Citigroup Inc Axsome Therapeutics, Inc. Transaction History

Citigroup Inc

$150 Billion
Q1 2024

A detailed history of Citigroup Inc transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 95,072 shares of AXSM stock, worth $7.5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

95,072

Previous 101,727 6.54%

Holding current value

$7.5 Million

Previous $8.1 Million 6.3%

% of portfolio

0.01%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$69.39 - $97.64 $461,790 - $649,794	-6,655 Reduced 6.54%	95,072 $7.59 Million
Q4 2023 Feb 09, 2024	SELL	$57.42 - $83.61 $53,687 - $78,175	-935 Reduced 0.91%	101,727 $8.1 Million
Q3 2023 Nov 09, 2023	BUY	$69.25 - $82.21 $2.76 Million - $3.28 Million	39,904 Added 63.58%	102,662 $7.18 Million
Q2 2023 Aug 10, 2023	BUY	$58.41 - $90.35 $843,206 - $1.3 Million	14,436 Added 29.87%	62,758 $4.51 Million
Q1 2023 May 11, 2023	BUY	$58.39 - $75.0 $451,004 - $579,300	7,724 Added 19.03%	48,322 $2.98 Million

Q4 2022 Feb 09, 2023	SELL	$39.94 - $79.72 $311,811 - $622,374	-7,807 Reduced 16.13%	40,598 $3.13 Million
Q3 2022 Nov 10, 2022	SELL	$36.06 - $69.85 $408,956 - $792,168	-11,341 Reduced 18.98%	48,405 $2.16 Million
Q2 2022 Aug 10, 2022	BUY	$21.74 - $46.75 $1.11 Million - $2.38 Million	50,842 Added 571.0%	59,746 $2.29 Million
Q1 2022 May 12, 2022	SELL	$23.7 - $41.39 $80,106 - $139,898	-3,380 Reduced 27.52%	8,904 $370,000
Q4 2021 Feb 10, 2022	SELL	$30.7 - $43.36 $1.06 Million - $1.5 Million	-34,587 Reduced 73.79%	12,284 $464,000
Q3 2021 Nov 10, 2021	BUY	$19.91 - $68.26 $933,201 - $3.2 Million	46,871 New	46,871 $1.55 Million

Others Institutions Holding AXSM

# of Institutions

290

Shares Held

37.1M

Call Options Held

401K

Put Options Held

464K

View Full List

About Axsome Therapeutics, Inc.

Ticker AXSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,878,000
Market Cap $3.38B
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...

More about AXSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account